Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-14-389643
Filing Date
2014-10-30
Accepted
2014-10-30 16:12:20
Documents
11
Period of Report
2014-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d778073d10q.htm 10-Q 557420
2 EX-31.1 d778073dex311.htm EX-31.1 5910
3 EX-31.2 d778073dex312.htm EX-31.2 5893
4 EX-32.1 d778073dex321.htm EX-32.1 2448
5 EX-32.2 d778073dex322.htm EX-32.2 2417
  Complete submission text file 0001193125-14-389643.txt   4141136

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT ogxi-20140930.xml EX-101.INS 517348
7 XBRL TAXONOMY EXTENSION SCHEMA ogxi-20140930.xsd EX-101.SCH 39567
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ogxi-20140930_cal.xml EX-101.CAL 52954
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ogxi-20140930_def.xml EX-101.DEF 164607
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE ogxi-20140930_lab.xml EX-101.LAB 338252
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ogxi-20140930_pre.xml EX-101.PRE 251191
Mailing Address 1522 217TH PLACE S.E. BOTHELL WA 98021
Business Address 1522 217TH PLACE S.E. BOTHELL WA 98021 4254879500
ONCOGENEX PHARMACEUTICALS, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 141183378
SIC: 2835 In Vitro & In Vivo Diagnostic Substances